Journals / Güncel Retina Dergisi / 2020 / Cilt: 4 - Sayı: 3

Current Management of Combined Traction/Rhegmatogenous Retinal Detachments

Kombine Traksiyonel/Yırtıklı Retina Dekolmanlarına Güncel Yaklaşım

Pages
212–219
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As long as the vitreoretinal surgery equipment and technics improved, the functional and anatomical success in CTRD and TRD will increase.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Due to proliferative diabetic retinopathy (PDR) and related complications, 25% of diabetic patients experience significant visual impairment.
📊
Key Findings & Data:TRD and CTRD which elevate macula less than 6 months, rapidly progressive and threatening macula are the other important indications to vitreoretinal surgery in diabetic retinopathy.
💡
Conclusion & Impact:As long as the vitreoretinal surgery equipment and technics improved, the functional and anatomical success in CTRD and TRD will increase.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Due to proliferative diabetic retinopathy (PDR) and related complications, 25% of diabetic patients experience significant visual impairment. Panretinal argon laser photocoagulation (PRP) and the use of vascular endothelial growth factors (VEGF) in recent years have reduced the frequency of visual loss and tractional retinal detachment (TRD) and combined tractional/ rhegmatogenous retinal detachment (CTRD). TRD and CTRD are the primary indications for vitreoretinal surgery related to PDR. TRD and CTRD which elevate macula less than 6 months, rapidly progressive and threatening macula are the other important indications to vitreoretinal surgery in diabetic retinopathy. CTRD, which was almost inoperable in previous years, now it takes place in the indications to vitreoretinal surgery by the development of new surgical equipment (vertical and horizontal scissors, light systems, diamond knives, trocar systems, etc.) and new surgical techniques (segmentation, visco-dissection, en-block dissection). Small calibered (23, 25, 27 Gauge) vitrectomy probes shortened the duration of vitreoretinal surgery in TRD and CTRD cases. Preoperative anti-VEGF treatment inhibits the fibrovascular tissue activation in this way facilitates and enables a safe surgery. As long as the vitreoretinal surgery equipment and technics improved, the functional and anatomical success in CTRD and TRD will increase.

Özet

Diyabetik hastalarının (DR) yüzde yirmi beşi proliferatif diyabetik retinopati (PDR) ve ilişkili komplikasyonlar sebebiyle görme keskinliklerini önemli ölçüde yitirmektedirler. Pan-retinal argon fotokoagülasyon (PRP) ve son yıllarda vasküler endotelyal growth faktör (VEGF) inhibitörlerinin kullanımı ile görme kayıpları ve PDR’ye bağlı traksiyonel retina dekolmanı (TRD) ve kombine traksiyonel/regmatojen retina dekolmanı (KTRD) görülme sıklığını azalmıştır. TRD ve KTRD PDR’ye bağlı vitreoretinal cerrahi endikasyonlarında ilk sırada yer almaktadırlar. 6 aydan daha kısa süreli makülayı eleve eden TRD, makülayı tehdit eden hızlı ilerleyen TRD ve KTRD önemli vitrektomi endikasyonlarıdır. KTRD çok eski yıllarda neredeyse inoperable kabul edilmesine rağmen vitreoretinal cerrahi enstrümanların gelişimi (vertikal, horizontal makaslar, ışık sistemleri, elmas uçlu bıçaklar, trokar sistemleri gibi.) ve vitreoretinal cerrahi tekniklerin (segmentasyon, viskodiseksiyon, en-blok diseksiyon gibi.) tanımlanması ile günümüzde PDR’ye bağlı vitrektomi endikasyonlarında yerini almıştır. Küçük çaplı vitrektomi problarının (23, 25, 27 Gauge) kullanımı ile gerek TRD ve gerekse KTRD cerrahi süresi oldukça kısalmıştır. Preoperatif uygulanan anti-VEGF tedaviler ile fibrovasküler doku aktivasyonu azaltılarak daha kolay ve güvenli cerrahi yapılması sağlanmıştır. Vitreoretinal cerrahi enstrümanlar ve teknikler geliştikçe KTRD ve TRD cerrahilerinde fonksiyonel ve anatomik başarı artacaktır.

🔖

Cite This Article

ÇINAR, E., ERAKGÜN, E. T. (2020). Current Management of Combined Traction/Rhegmatogenous Retinal Detachments. Güncel Retina Dergisi, Cilt: 4 - Sayı: 3, 212–219. https://ajindex.com/articles/158911

References (14)

  1. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122(4):552-563
  2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35(3):556-564
  3. Ferris FL 3rd. Results of 20 years of research on the treatment of diabetic retinopathy. Prev Med 1994;23(5):740-742
  4. Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd, et al. Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The early treatment diabetic retinopathy study research group. Ophthalmology 1992;99(9):1351-1357
  5. Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: A pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971;75(4):813-820
  6. Aaberg TM. Vitrectomy for diabetic retinopathy. In: Freeman HM, Hirose T, Schepens CL, editors. Vitreous Surgery and Advances in Fundus Diagnosis and Treatment. New York: Appleton-Century-Crofts; 1977. p. 297-313
  7. La Heij EC, Tecim S, Kessels AG, Liem AT, Japing WJ, Hendrikse F, et al. Clinical variables and their relation to visual outcome after vitrectomy in eyes with diabetic retinal traction detachment. Graefes Arch Clin Exp Ophthalmol 2004;242(3):210-217
  8. Aaberg TM, Abrams GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology 1987;94(7):775-779
  9. Harbour JW, Smiddy WE, Flynn HW Jr. Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996;121(4):405-413
  10. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994(22);331:1480- 1487
  11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-820
  12. Diederen RM, La Heij EC, Deutz NE, Kessels AG, van Eijk HM, Hendrikse F, et al. Increased nitric oxide (NO) pathway metabolites in the vitreous fluid of patients with rhegmatogenous retinal detachment or diabetic traction retinal. Graefes Arch Clin Exp Ophthalmol. 2006;244(6):683-688
  13. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996;10(3-4):179-190
  14. Dai Y, Wu Z, Wang F, Zhang Z, Yu M. Identif